TITLE

Preserving beta-cell function in DM2

PUB. DATE
August 2009
SOURCE
Neurology Alert;Aug2009 Clinical Briefs in, Vol. 14 Issue 8, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article provides a comparison on the one-year treatment of patients suffering from metformin-treated type 2 diabetes with exenatide and treatment with insulin glargine to improve beta-cell function. It references a study by MC Bunck and others, published in the 2009 issue of "Diabetes Care." The research shows that after one-year treatment with either exenatide or insulin, body weight of the patients varied and beta-cell function improved on exenatide but remained unchanged on insulin.
ACCESSION #
44156771

 

Related Articles

  • Dual Mechanism for Type-2 Diabetes Resolution after Roux-en-Y Gastric Bypass. LIN, EDWARD; DAVIS, S. SCOTT; SRINIVASAN, JAHNAVI; SWEENEY, JOHN F.; ZIEGLER, THOMAS R.; PHILLIPS, LAWRENCE; GLETSU-MILLER, NANA // American Surgeon;Jun2009, Vol. 75 Issue 6, p498 

    Resolution of Type-2 diabetes mellitus (DM) after weight toss surgery is well documented, but the mechanism is elusive. We evaluated the glucose-insulin metabolism of patients undergoing a Roux-en-Y gastric bypass (RYGB) using the intravenous glucose tolerance test (IVGTT) and compared it with...

  • Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. Tanaka, Kumiko; Saisho, Yoshifumi; Manesso, Erica; Tanaka, Masami; Meguro, Shu; Irie, Junichiro; Sugiura, Hiroaki; Kawai, Toshihide; Jinzaki, Masahiro; Cobelli, Claudio; Itoh, Hiroshi // Clinical Drug Investigation;Oct2015, Vol. 35 Issue 10, p675 

    Background and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming one of the major therapeutic options for the treatment of type 2 diabetes mellitus (T2DM). This study was conducted as an exploratory analysis to clarify the effects of liraglutide, a GLP-1RA, on beta...

  • Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes. BUNCK, MATHIJS C.; CORNÉR, ANJA; ELIASSON, BJORN; HEINE, ROBERT J.; SHAGINIAN, RIMMA M.; TASKINEN, MARJA-RIITTA; SMITH, ULF; YKI-JÄRVINEN, HANNELE; DIAMANT, MICHAELA // Diabetes Care;Sep2011, Vol. 34 Issue 9, p2041 

    OBJECTIVE--We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after...

  • Pioglitazone reduces the risk of converting impaired glucose tolerance to type 2 diabetes.  // Australian Journal of Pharmacy;Aug2011, Vol. 92 Issue 1095, p82 

    The article focuses on a study which examined whether pioglitazone could reduce the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus in adults. It says that the study evaluated data gathered on 602 patients, who received pioglitazone or placebo and had an annual oral...

  • The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin. Stocker, S L; Morrissey, K M; Yee, S W; Castro, R A; Xu, L; Dahlin, A; Ramirez, A H; Roden, D M; Wilke, R A; McCarty, C A; Davis, R L; Brett, C M; Giacomini, K M // Clinical Pharmacology & Therapeutics;Feb2013, Vol. 93 Issue 2, p186 

    Interindividual variation in response to metformin, first-line therapy for type 2 diabetes, is substantial. Given that transporters are determinants of metformin pharmacokinetics, we examined the effects of promoter variants in both multidrug and toxin extrusion protein 1 (MATE1)...

  • Combination sitagliptin/metformin improved beta cell function, HbA1c. Barzilai, Nir; Grassia, Tara; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p7 

    The article discusses a study which examined the effect of initial combination therapy with sitagliptin and metformin. Patients were randomly assigned to one of five treatment groups. Results showed that the therapy improved blood glucose levels and markers of beta cell function in patients with...

  • Goals of Treatment for Type 2 Diabetes. Marchetti, Piero; Lupi, Roberto; Del Guerra, Silvia; Bugliani, Marco; D'Aleo, Valentina; Occhipinti, Margherita; Boggi, Ugo; Marselli, Lorella; Masini, Matilde // Diabetes Care;Nov2009 Supplement, Vol. 32, pS178 

    The article discusses the possibility to treat type 2 diabetes by preserving β-cells and preventing the deterioration of glucose control. The findings of several studies on β-cell function among subjects with normal and impaired glucose tolerance are tackled. Also tackled are the effects...

  • Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diamant, Michaela; Nauck, Michael A.; Shaginian, Rimma; Malone, James K.; Cleall, Simon; Reaney, Matthew; de Vries, Danielle; Hoogwerf, Byron J.; MacConell, Leigh; Wolffenbuttel, Bruce H. R. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2763 

    OBJECTIVE Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is associated with weight gain and hypoglycemia. This study compared the efficacy and safety of exenatide twice daily or mealtime insulin...

  • Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin. NAUCK, MICHAEL A.; DEL PRATO, STEFANO; MEIER, JURIS J.; DURÁN-GARCÍA, SANTIAGO; ROHWEDDER, KATJA; ELZE, MARTINA; PARIKH, SHAMIK J. // Diabetes Care;Sep2011, Vol. 34 Issue 9, p2015 

    OBJECTIVE--Although initially effective, sulfonylureas are associated with poor glycemic durability, weight gain, and hypoglycemia. Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (5GLT2), reduces hyperglycemia by increasing urinary glucose excretion independent of insulin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics